In the first stage of trials, the vaccine was tested on morethan 1,000 healthy adult volunteers aged between 18 and 55 years. Business Secretary Alok Sharma said: “Today’s results areextremely encouraging, taking us one step closer to finding a successfulvaccine to protect millions in the UK and across the world. Researchers will now focus on confirming that the virus can effectively protect against SARs-CoV-2 infection. This trial drew from young, healthy, British volunteers. The authors of the study have stated that “Phase 3 trials are now underway in Brazil, South Africa, and the UK and will evaluate vaccine efficacy in diverse populations”. Additionally, “Older age groups with comorbidities, health-care workers, and those with higher risk for SARS-CoV-2 exposure are being recruited and assessed.” Image attribution: https://pixabay.com/photos/laboratory-medical-medicine-hand-3827745/ The University of Oxford coronavirus vaccine appears totrain the immune system without safety concerns, theUniversity has announced. “We saw the strongest immune response in the 10 participantswho received two doses of the vaccine, indicating that this might be a goodstrategy for vaccination.” Tests show the vaccine produced white blood cells within 14 days of vaccination and an antibody response within 28 days. The strongest immune responses occurred in the ten participants who received two doses of the vaccine. “The immune responses observed following vaccination are inline with what previous animal studies have shown are associated withprotection against the SARS-CoV-2 virus, although we must continue with ourrigorous clinical trial programme to confirm this in humans.” “Backed by £84 million Government investment for the vaccine’s development and manufacture, the agility and speed with which the University of Oxford have been working is outstanding. I am very proud of what they have achieved so far.” Participants had detectable neutralising antibodies, which researchers believe is important for protection. 100% of participants showed neutralising activity against the virus. The strength of response ranged, but vaccine antibody levels were in the same range as those of people who had previously had COVID-19. The Chief investigator of the trial, Professor Andrew Pollard, said: “The Phase I/II data for our coronavirus vaccine shows that the vaccine did not lead to any unexpected reactions and had a similar safety profile to previous vaccines of this type. The University is working with the biopharmaceutical company AstraZeneca for further development.